NO318237B1 - Fremgangsmate i produksjonsskala for dannelse av mikropartikler - Google Patents

Fremgangsmate i produksjonsskala for dannelse av mikropartikler Download PDF

Info

Publication number: NO318237B1
Authority: NO; Norway
Prior art keywords: solvent; microdroplets; liquefied gas; container; freezing
Prior art date: 1995-05-18

Application number

NO19975269A

Other languages

English (en)

Norwegian (no)

Other versions

NO975269D0 (no

NO975269L (no

Inventor

Paul F Herbert

Michael S Healy

Original Assignee

Alkermes Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-18

Filing date

1997-11-17

Publication date

2005-02-21

1997-11-17 Application filed by Alkermes Inc filed Critical Alkermes Inc

1997-11-17 Publication of NO975269D0 publication Critical patent/NO975269D0/no

1998-01-15 Publication of NO975269L publication Critical patent/NO975269L/no

2005-02-21 Publication of NO318237B1 publication Critical patent/NO318237B1/no

Links

239000011859 microparticle Substances 0.000 title claims abstract description 69
238000000034 method Methods 0.000 title claims abstract description 55
230000015572 biosynthetic process Effects 0.000 title description 9
238000004519 manufacturing process Methods 0.000 title description 3
239000002904 solvent Substances 0.000 claims abstract description 97
238000007710 freezing Methods 0.000 claims abstract description 70
230000008014 freezing Effects 0.000 claims abstract description 70
239000000463 material Substances 0.000 claims abstract description 55
239000007788 liquid Substances 0.000 claims abstract description 27
238000000605 extraction Methods 0.000 claims description 76
229920000642 polymer Polymers 0.000 claims description 46
239000013543 active substance Substances 0.000 claims description 24
239000003795 chemical substances by application Substances 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 16
229940079593 drug Drugs 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 12
108090000623 proteins and genes Proteins 0.000 claims description 12
102000004169 proteins and genes Human genes 0.000 claims description 12
-1 antibodies Proteins 0.000 claims description 7
229920001577 copolymer Polymers 0.000 claims description 5
108090000765 processed proteins & peptides Proteins 0.000 claims description 5
239000002246 antineoplastic agent Substances 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
239000004814 polyurethane Substances 0.000 claims description 4
229920002635 polyurethane Polymers 0.000 claims description 4
229940002612 prodrug Drugs 0.000 claims description 4
239000000651 prodrug Substances 0.000 claims description 4
239000000427 antigen Substances 0.000 claims description 3
108091007433 antigens Proteins 0.000 claims description 3
102000036639 antigens Human genes 0.000 claims description 3
229940088597 hormone Drugs 0.000 claims description 3
239000005556 hormone Substances 0.000 claims description 3
229920000747 poly(lactic acid) Polymers 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 2
102000004127 Cytokines Human genes 0.000 claims description 2
108090000695 Cytokines Proteins 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
108090000394 Erythropoietin Proteins 0.000 claims description 2
102000003951 Erythropoietin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
108010063738 Interleukins Proteins 0.000 claims description 2
102000015696 Interleukins Human genes 0.000 claims description 2
101710163270 Nuclease Proteins 0.000 claims description 2
229920002732 Polyanhydride Polymers 0.000 claims description 2
229920001710 Polyorthoester Polymers 0.000 claims description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
229940035674 anesthetics Drugs 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000000118 anti-neoplastic effect Effects 0.000 claims description 2
230000000692 anti-sense effect Effects 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
229940125715 antihistaminic agent Drugs 0.000 claims description 2
239000000739 antihistaminic agent Substances 0.000 claims description 2
229940034982 antineoplastic agent Drugs 0.000 claims description 2
239000002327 cardiovascular agent Substances 0.000 claims description 2
229940125692 cardiovascular agent Drugs 0.000 claims description 2
229940047120 colony stimulating factors Drugs 0.000 claims description 2
239000000850 decongestant Substances 0.000 claims description 2
229940124581 decongestants Drugs 0.000 claims description 2
229940105423 erythropoietin Drugs 0.000 claims description 2
239000003193 general anesthetic agent Substances 0.000 claims description 2
239000003102 growth factor Substances 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
229940047124 interferons Drugs 0.000 claims description 2
229940047122 interleukins Drugs 0.000 claims description 2
229920001308 poly(aminoacid) Polymers 0.000 claims description 2
229920001610 polycaprolactone Polymers 0.000 claims description 2
239000004632 polycaprolactone Substances 0.000 claims description 2
239000004417 polycarbonate Substances 0.000 claims description 2
229920000515 polycarbonate Polymers 0.000 claims description 2
229920002721 polycyanoacrylate Polymers 0.000 claims description 2
229920006149 polyester-amide block copolymer Polymers 0.000 claims description 2
229920006324 polyoxymethylene Polymers 0.000 claims description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
239000000932 sedative agent Substances 0.000 claims description 2
229940125723 sedative agent Drugs 0.000 claims description 2
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 2
102000003390 tumor necrosis factor Human genes 0.000 claims description 2
239000011782 vitamin Substances 0.000 claims description 2
229940088594 vitamin Drugs 0.000 claims description 2
229930003231 vitamin Natural products 0.000 claims description 2
235000013343 vitamin Nutrition 0.000 claims description 2
229920000954 Polyglycolide Polymers 0.000 claims 1
229940088598 enzyme Drugs 0.000 claims 1
239000007789 gas Substances 0.000 description 139
239000000243 solution Substances 0.000 description 44
239000007921 spray Substances 0.000 description 22
238000002156 mixing Methods 0.000 description 21
239000012071 phase Substances 0.000 description 18
238000013467 fragmentation Methods 0.000 description 15
238000006062 fragmentation reaction Methods 0.000 description 15
238000010438 heat treatment Methods 0.000 description 12
239000002245 particle Substances 0.000 description 12
239000007787 solid Substances 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
230000008018 melting Effects 0.000 description 8
238000002844 melting Methods 0.000 description 8
239000000839 emulsion Substances 0.000 description 7
239000012530 fluid Substances 0.000 description 7
239000004005 microsphere Substances 0.000 description 7
238000004891 communication Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000004094 surface-active agent Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
229920002988 biodegradable polymer Polymers 0.000 description 5
239000004621 biodegradable polymer Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
238000000638 solvent extraction Methods 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
229920000249 biocompatible polymer Polymers 0.000 description 3
239000004067 bulking agent Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
229910001873 dinitrogen Inorganic materials 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000002184 metal Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
239000000047 product Substances 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
230000003068 static effect Effects 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
238000009835 boiling Methods 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000036512 infertility Effects 0.000 description 2
239000011810 insulating material Substances 0.000 description 2
238000009413 insulation Methods 0.000 description 2
239000012774 insulation material Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
230000003134 recirculating effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
241001082241 Lythrum hyssopifolia Species 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
240000007182 Ochroma pyramidale Species 0.000 description 1
101100419716 Podospora anserina RPS9 gene Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000012865 aseptic processing Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
238000010923 batch production Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000007799 cork Substances 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940095399 enema Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HDERJYVLTPVNRI-UHFFFAOYSA-N ethene;ethenyl acetate Chemical class C=C.CC(=O)OC=C HDERJYVLTPVNRI-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
229920001821 foam rubber Polymers 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
VWQWXZAWFPZJDA-CGVGKPPMSA-N hydrocortisone succinate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 VWQWXZAWFPZJDA-CGVGKPPMSA-N 0.000 description 1
229950006240 hydrocortisone succinate Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000001788 irregular Effects 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229940065514 poly(lactide) Drugs 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
238000012667 polymer degradation Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
229920002620 polyvinyl fluoride Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000004886 process control Methods 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000004576 sand Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000002912 waste gas Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/12—Making granules characterised by structure or composition
- B29B2009/125—Micropellets, microgranules, microparticles

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Physical Or Chemical Processes And Apparatus (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Inorganic Compounds Of Heavy Metals (AREA)
Extraction Or Liquid Replacement (AREA)

NO19975269A 1995-05-18 1997-11-17 Fremgangsmate i produksjonsskala for dannelse av mikropartikler NO318237B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/443,726 US5922253A (en)	1995-05-18	1995-05-18	Production scale method of forming microparticles
PCT/US1996/006889 WO1996036317A1 (en)	1995-05-18	1996-05-15	Production scale method of forming microparticles

Publications (3)

Publication Number	Publication Date
NO975269D0 NO975269D0 (no)	1997-11-17
NO975269L NO975269L (no)	1998-01-15
NO318237B1 true NO318237B1 (no)	2005-02-21

Family

ID=23761943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19975269A NO318237B1 (no)	1995-05-18	1997-11-17	Fremgangsmate i produksjonsskala for dannelse av mikropartikler

Country Status (22)

Country	Link
US (5)	US5922253A (pl)
EP (1)	EP0827396B1 (pl)
JP (1)	JP4226649B2 (pl)
KR (1)	KR100475476B1 (pl)
CN (1)	CN1153567C (pl)
AT (1)	ATE236618T1 (pl)
AU (1)	AU701992B2 (pl)
BR (1)	BR9608370A (pl)
CA (1)	CA2221496C (pl)
CZ (1)	CZ292969B6 (pl)
DE (1)	DE69627320T2 (pl)
DK (1)	DK0827396T3 (pl)
ES (1)	ES2197239T3 (pl)
HU (1)	HU224194B1 (pl)
MX (1)	MX9708777A (pl)
NO (1)	NO318237B1 (pl)
NZ (1)	NZ308763A (pl)
PL (1)	PL184484B1 (pl)
PT (1)	PT827396E (pl)
RU (1)	RU2159148C2 (pl)
SK (1)	SK283128B6 (pl)
WO (1)	WO1996036317A1 (pl)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6051256A (en)	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
US5922253A (en) *	1995-05-18	1999-07-13	Alkermes Controlled Therapeutics, Inc.	Production scale method of forming microparticles
US20030203036A1 (en)	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
SE9801288D0 (sv)	1998-04-14	1998-04-14	Astra Ab	Vaccine delivery system and metod of production
GB9819272D0 (en) *	1998-09-03	1998-10-28	Andaris Ltd	Microparticles
DE60026982T2 (de) *	1999-04-05	2006-11-16	Mannkind Corp., Danbury	Verfahren zur bildung von feinem pulver
EP1658840A1 (en) *	1999-04-05	2006-05-24	Mannkind Corporation	Methods for fine powder formation
US6291013B1 (en)	1999-05-03	2001-09-18	Southern Biosystems, Inc.	Emulsion-based processes for making microparticles
US6444223B1 (en)	1999-05-28	2002-09-03	Alkermes Controlled Therapeutics, Inc.	Method of producing submicron particles of a labile agent and use thereof
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US6284283B1 (en) *	1999-10-21	2001-09-04	Alkermes Controlled Therapeutics, Inc.	Method of producing sub-micron particles of biologically active agents and uses thereof
US6465425B1 (en)	2000-02-10	2002-10-15	Alkermes Controlled Therapeutics, Inc.	Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
GB0004827D0 (en) *	2000-02-29	2000-04-19	Quadrant Holdings Cambridge	Compositions
DE60119696T2 (de)	2000-03-15	2007-01-25	Wolfgang Ross Sadee	Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
US6495164B1 (en)	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
US7575761B2 (en)	2000-06-30	2009-08-18	Novartis Pharma Ag	Spray drying process control of drying kinetics
US6719970B1 (en)	2000-07-10	2004-04-13	Alkermes Controlled Therapeutics, Inc.	Method of generating cartilage
WO2002009669A2 (en) *	2000-08-01	2002-02-07	Inhale Therapeutic Systems, Inc.	Apparatus and process to produce particles having a narrow size distribution and particles made thereby
US6479065B2 (en)	2000-08-10	2002-11-12	Alkermes Controlled Therapeutics, Inc.	Process for the preparation of polymer-based sustained release compositions
US6296842B1 (en)	2000-08-10	2001-10-02	Alkermes Controlled Therapeutics, Inc.	Process for the preparation of polymer-based sustained release compositions
EP1355630B1 (en)	2000-08-15	2009-11-25	The Board Of Trustees Of The University Of Illinois	Method of forming microparticles
US6824822B2 (en)	2001-08-31	2004-11-30	Alkermes Controlled Therapeutics Inc. Ii	Residual solvent extraction method and microparticles produced thereby
US7241742B2 (en)	2000-10-31	2007-07-10	Mgi Pharma Biologics, Inc.	CYP1B1 nucleic acids and methods of use
US6558702B2 (en) *	2001-04-13	2003-05-06	Alkermes Controlled Therapeutics, Inc.	Method of modifying the release profile of sustained release compositions
US20060269602A1 (en) *	2001-04-13	2006-11-30	Dasch James R	Method of modifying the release profile of sustained release compositions
EP1389468A4 (en) *	2001-05-23	2007-01-10	Tanabe Seiyaku Co	COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
CN1537018A (zh) *	2001-05-23	2004-10-13	田边制药株式会社	一种用于软骨疾病再生治疗的组合物
US6730772B2 (en)	2001-06-22	2004-05-04	Venkatram P. Shastri	Degradable polymers from derivatized ring-opened epoxides
EP1445282A4 (en) *	2001-08-03	2004-11-24	Toray Industries	RESIN COMPOSITION AND MOLDED ARTICLE, FILM AND FIBER
KR100951750B1 (ko) *	2001-11-01	2010-04-09	노바르티스 아게	분무 건조 방법 및 그 조성물
WO2003066585A2 (en) *	2002-02-08	2003-08-14	Alkermes Controlled Therapeutics, Inc.	Polymer-based compositions for sustained release
AU2003219805B2 (en) *	2002-02-15	2009-06-04	Eisai Inc.	Electroporation methods for introducing bioactive agents into cells
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
WO2003087189A1 (en) *	2002-04-05	2003-10-23	Valorisation - Recherche, Societe En Commandite	Functionalized polymers and their biomedical and pharmaceutical uses
GB0216562D0 (en)	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
DE10234165B4 (de) *	2002-07-26	2008-01-03	Advanced Micro Devices, Inc., Sunnyvale	Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
DE10243483A1 (de) *	2002-09-19	2004-04-08	Messer Griesheim Gmbh	System zum Mikropelletieren von Lösungen bzw. Schmelzen
WO2004035762A2 (en) *	2002-10-17	2004-04-29	Alkermes Controlled Therapeutics, Inc. Ii	Microencapsulation and sustained release of biologically active polypeptides
US6800663B2 (en) *	2002-10-18	2004-10-05	Alkermes Controlled Therapeutics Inc. Ii,	Crosslinked hydrogel copolymers
US7658998B2 (en) *	2003-01-22	2010-02-09	Alkermes Controlled Therapeutics, Inc.	Method of preparing sustained release microparticles
US20040197413A1 (en) *	2003-04-04	2004-10-07	Genteric, Inc.	Spray dry coacervation systems and methods
EP1628664A4 (en) *	2003-06-04	2008-11-05	Alkermes Inc	POLYMORPHIC FORMS OF NALTREXONE
US6987111B2 (en)	2003-08-06	2006-01-17	Alkermes Controlled Therapeutics, Ii	Aripiprazole, olanzapine and haloperidol pamoate salts
WO2005042219A1 (en) *	2003-10-24	2005-05-12	Ferro Corporation	Method of forming particles
US7309500B2 (en) *	2003-12-04	2007-12-18	The Board Of Trustees Of The University Of Illinois	Microparticles
WO2005072702A2 (en) *	2004-01-20	2005-08-11	Alkermes Controlled Therapeutics, Inc.	Method for milling frozen microparticles
US20050245541A1 (en) *	2004-03-19	2005-11-03	Elliot Ehrich	Methods for treating alcoholism
US20050245461A1 (en) *	2004-03-19	2005-11-03	Elliot Ehrich	Methods for treating alcoholism
US20060110423A1 (en) *	2004-04-15	2006-05-25	Wright Steven G	Polymer-based sustained release device
US7456254B2 (en) *	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
US8617613B2 (en)	2004-04-15	2013-12-31	Alkermes Pharma Ireland Limited	Polymer-based sustained release device
US7919499B2 (en)	2004-04-22	2011-04-05	Alkermes, Inc.	Naltrexone long acting formulations and methods of use
EP1750683B1 (en) *	2004-04-23	2013-01-09	Amgen Inc.	Sustained release formulations
EP1749039A1 (en) *	2004-04-23	2007-02-07	Amgen Inc.	Low molecular weight polylactic acid polymers
WO2005107714A2 (en) *	2004-05-05	2005-11-17	Alkermes Controlled Therapeutics, Inc.	Method of forming microparticles that include a bisphosphonate and a polymer
EP1604693A1 (en)	2004-06-09	2005-12-14	Scil Technology GmbH	In situ forming scaffold, its manufacturing and use
US20100112028A1 (en) *	2004-06-09	2010-05-06	Klaus Hellerbrand	Composite material for use as protein carrier
WO2006078320A2 (en)	2004-08-04	2006-07-27	Brookwood Pharmaceuticals, Inc.	Methods for manufacturing delivery devices and devices thereof
PL1786784T3 (pl)	2004-08-20	2011-04-29	Mannkind Corp	Kataliza syntezy diketopiperazyn
KR101644250B1 (ko)	2004-08-23	2016-07-29	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US7733294B2 (en) *	2004-11-03	2010-06-08	Sony Corporation	Method and system for wireless transmission
TW200621310A (en) *	2004-11-10	2006-07-01	Univ Groningen	A process for preparing formulations of lypophilic active substances by spray freeze drying
US20070098864A1 (en) *	2004-11-10	2007-05-03	Zijlstra Gerrit S	Process for preparing formulations of lypophilic active substances by spray freezing drying
US7748343B2 (en)	2004-11-22	2010-07-06	The Board Of Trustees Of The University Of Illinois	Electrohydrodynamic spraying system
CN101115475A (zh)	2004-12-10	2008-01-30	塔利马治疗公司	用于治疗指甲单位病症的组合物和方法
US20060275230A1 (en)	2004-12-10	2006-12-07	Frank Kochinke	Compositions and methods for treating conditions of the nail unit
WO2006078841A1 (en) *	2005-01-21	2006-07-27	President And Fellows Of Harvard College	Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
US7252834B2 (en)	2005-04-25	2007-08-07	Clemson University Research Foundation (Curf)	Elastin stabilization of connective tissue
US20080095849A1 (en) *	2005-04-25	2008-04-24	Amgen Inc.	Peptide sustained release compositions and uses thereof
CN104324362B (zh)	2005-09-14	2018-04-24	曼金德公司	以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
RU2300369C1 (ru) *	2005-12-27	2007-06-10	Наталья Ивановна Ларионова	Способ получения полиэлектролитных микрочастиц, содержащих инкапсулируемое вещество, чувствительных к изменению состава окружающей среды
IN2015DN00888A (pl)	2006-02-22	2015-07-10	Mannkind Corp
US7403325B2 (en) *	2006-05-19	2008-07-22	Xerox Corporation	Electrophoretic display device
US20080075777A1 (en) *	2006-07-31	2008-03-27	Kennedy Michael T	Apparatus and methods for preparing solid particles
TWI318894B (en) *	2006-08-07	2010-01-01	Ind Tech Res Inst	System for fabricating nano particles
EP2359808B1 (en)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotic delivery systems and piston assemblies
CA2667890C (en)	2006-10-31	2015-01-27	Surmodics Pharmaceuticals, Inc.	Spheronized polymer particles
US20080098900A1 (en) *	2006-11-01	2008-05-01	Babatunde Aremu	Beverage manufacture using a static mixer
GB0625322D0 (en) *	2006-12-19	2007-01-24	Pharmakodex Ltd	Pharmaceutical compositions
AU2008231093A1 (en) *	2007-03-22	2008-10-02	Alkermes, Inc.	Coacervation process
GB0707612D0 (en)	2007-04-19	2007-05-30	Stratosphere Pharma Ab	Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
WO2008133908A2 (en)	2007-04-23	2008-11-06	Intarcia Therapeutics, Inc.	Suspension formulations of insulinotropic peptides and uses thereof
WO2008156356A1 (en) *	2007-06-19	2008-12-24	Feyecon Development & Implementation B.V.	Preparation of a pharmaceutically active ingredient comprising a desolventising step
US20080317865A1 (en) *	2007-06-20	2008-12-25	Alkermes, Inc.	Quench liquids and washing systems for production of microparticles
UA96342C2 (en) *	2007-06-25	2011-10-25	Оцука Фармасьютикал Ко., Лтд.	Microspheres having core/shell structure
JP2011500686A (ja) *	2007-10-18	2011-01-06	アイコバイオテクノロジー	オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
US8748448B2 (en)	2007-10-18	2014-06-10	Aiko Biotechnology	Combination analgesic employing opioid agonist and neutral antagonist
WO2009085952A1 (en)	2007-12-20	2009-07-09	Brookwood Pharmaceuticals, Inc.	Process for preparing microparticles having a low residual solvent volume
JP2009207120A (ja) *	2008-02-01	2009-09-10	Ricoh Co Ltd	画像形成装置管理システム及び画像形成装置管理方法
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
US20090214654A1 (en) *	2008-02-21	2009-08-27	Isenburg Jason C	Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
CN101959527B (zh)	2008-03-05	2016-04-20	赛诺菲巴斯德有限公司	一种使含佐剂的疫苗组合物稳定的方法
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
KR101628410B1 (ko)	2008-06-20	2016-06-08	맨카인드 코포레이션	흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법
EP2143440A1 (fr)	2008-07-09	2010-01-13	Sanofi Pasteur	Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US20100119605A1 (en) *	2008-11-12	2010-05-13	Isenburg Jason C	Compositions for tissue stabilization
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US20100189800A1 (en) *	2009-01-23	2010-07-29	Peter Markland	Continous double emulsion process for making microparticles
US20100196436A1 (en) *	2009-01-30	2010-08-05	Gooberman Lance L	Implants containing disulfiram and an anti-inflammatory agent
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
US8791093B2 (en) *	2009-05-29	2014-07-29	Lance L. Gooberman	Pharmaceutical delivery systems for treatment of substance abuse and other addictions
CN104721825B (zh)	2009-06-12	2019-04-12	曼金德公司	具有确定比表面积的二酮哌嗪颗粒
RU2547990C2 (ru)	2009-09-28	2015-04-10	Интарсия Терапьютикс, Инк.	Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
WO2011044455A1 (en) *	2009-10-09	2011-04-14	Vatrix Medical, Inc.	In vivo chemical stabilization of vulnerable plaque
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
GB201016436D0 (en) *	2010-09-30	2010-11-17	Q Chip Ltd	Method of making solid beads
GB201016433D0 (en)	2010-09-30	2010-11-17	Q Chip Ltd	Apparatus and method for making solid beads
US8911468B2 (en)	2011-01-31	2014-12-16	Vatrix Medical, Inc.	Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
EP2709711B8 (en)	2011-05-18	2017-03-22	Vatrix Medical, Inc.	Coated balloons for blood vessel stabilization
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
CN104619369B (zh)	2012-07-12	2018-01-30	曼金德公司	干粉药物输送系统和方法
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
CN105377355A (zh)	2013-03-14	2016-03-02	拇趾公司	治疗甲单元的感染、疾病或病症的方法
AU2014228415B2 (en)	2013-03-15	2018-08-09	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US11446127B2 (en)	2013-08-05	2022-09-20	Mannkind Corporation	Insufflation apparatus and methods
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
RU2730996C2 (ru)	2015-06-03	2020-08-26	Интарсия Терапьютикс, Инк.	Системы установки и извлечения имплантата
KR102574993B1 (ko)	2016-05-16	2023-09-06	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
KR101942449B1 (ko) *	2016-12-13	2019-01-28	주식회사 삼양바이오팜	생분해성 고분자의 다공성 미립자, 및 이를 포함하는 고분자 필러
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
USD933219S1 (en)	2018-07-13	2021-10-12	Intarcia Therapeutics, Inc.	Implant removal tool and assembly
CN110694532B (zh) *	2019-09-16	2022-03-01	陕西中医药大学	一种药理学实验用的混合加热装置
KR102283250B1 (ko) *	2020-12-24	2021-07-29	(주)인벤티지랩	용매 제거 장치 및 이를 이용한 미소구체 제조 방법
CN112774571A (zh) *	2020-12-26	2021-05-11	深圳万和制药有限公司	高均匀性大粒径微丸的分散冷凝生产工艺
US11606756B2 (en)	2021-03-29	2023-03-14	Snap Inc.	Scheduling requests for location data
CN114160040B (zh) *	2021-12-09	2022-07-12	广州风行乳业股份有限公司	一种液氮深冷制粒设备

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL280825A (pl) *	1962-07-11
BE744162A (fr) *	1969-01-16	1970-06-15	Fuji Photo Film Co Ltd	Procede d'encapsulage
US3887699A (en) *	1969-03-24	1975-06-03	Seymour Yolles	Biodegradable polymeric article for dispensing drugs
DE2010115A1 (de) *	1970-03-04	1971-09-16	Farbenfabriken Bayer Ag, 5090 Leverkusen	Verfahren zur Herstellung von Mikrogranulaten
US3928566A (en) *	1970-08-14	1975-12-23	Du Pont	Lyophilized biological products
JPS523342B2 (pl) *	1972-01-26	1977-01-27
SE370626B (pl)	1973-03-02	1974-10-28	U Sweger
US4166800A (en) *	1977-08-25	1979-09-04	Sandoz, Inc.	Processes for preparation of microspheres
US4389330A (en) *	1980-10-06	1983-06-21	Stolle Research And Development Corporation	Microencapsulation process
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
US4530840A (en) *	1982-07-29	1985-07-23	The Stolle Research And Development Corporation	Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) *	1982-07-29	1985-09-17	The Stolle Research And Development Corporation	Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
CH661206A5 (fr) *	1983-09-23	1987-07-15	Debiopharm Sa	Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4804741A (en) *	1984-05-23	1989-02-14	Anver Bioscience Design, Inc.	Guayule rubber, resin and bagasse recovery and purification processes
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
WO1989003678A1 (en) *	1987-10-30	1989-05-05	Stolle Research & Development Corporation	Low residual solvent microspheres and microencapsulation process
ES2062530T3 (es) *	1989-05-01	1994-12-16	Alkermes Inc	Procedimiento para producir particulas pequeñas de moleculas biologicamente activas.
US5019400A (en) *	1989-05-01	1991-05-28	Enzytech, Inc.	Very low temperature casting of controlled release microspheres
US5288502A (en) *	1991-10-16	1994-02-22	The University Of Texas System	Preparation and uses of multi-phase microspheres
US5307640A (en)	1993-01-25	1994-05-03	E. I. Du Pont De Nemours And Company	Apparatus and method for producing frozen particles of a liquid
JPH06323712A (ja)	1993-04-20	1994-11-25	E I Du Pont De Nemours & Co	霧化した極低温液滴の閉じ込め帯域を用いて凍結粒子を製造する方法および装置
US5922253A (en) *	1995-05-18	1999-07-13	Alkermes Controlled Therapeutics, Inc.	Production scale method of forming microparticles
US5989463A (en) *	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices

1995
- 1995-05-18 US US08/443,726 patent/US5922253A/en not_active Expired - Lifetime
1996
- 1996-05-15 KR KR1019970708236A patent/KR100475476B1/ko not_active Expired - Fee Related
- 1996-05-15 CA CA002221496A patent/CA2221496C/en not_active Expired - Fee Related
- 1996-05-15 PT PT96920210T patent/PT827396E/pt unknown
- 1996-05-15 AT AT96920210T patent/ATE236618T1/de not_active IP Right Cessation
- 1996-05-15 DK DK96920210T patent/DK0827396T3/da active
- 1996-05-15 JP JP53498896A patent/JP4226649B2/ja not_active Expired - Fee Related
- 1996-05-15 EP EP96920210A patent/EP0827396B1/en not_active Expired - Lifetime
- 1996-05-15 PL PL96323382A patent/PL184484B1/pl not_active IP Right Cessation
- 1996-05-15 DE DE69627320T patent/DE69627320T2/de not_active Expired - Fee Related
- 1996-05-15 CZ CZ19973582A patent/CZ292969B6/cs not_active IP Right Cessation
- 1996-05-15 WO PCT/US1996/006889 patent/WO1996036317A1/en not_active Ceased
- 1996-05-15 RU RU97119048/12A patent/RU2159148C2/ru not_active IP Right Cessation
- 1996-05-15 NZ NZ308763A patent/NZ308763A/en not_active IP Right Cessation
- 1996-05-15 SK SK1537-97A patent/SK283128B6/sk not_active IP Right Cessation
- 1996-05-15 CN CNB961939109A patent/CN1153567C/zh not_active Expired - Fee Related
- 1996-05-15 HU HU9802489A patent/HU224194B1/hu not_active IP Right Cessation
- 1996-05-15 BR BR9608370A patent/BR9608370A/pt not_active Application Discontinuation
- 1996-05-15 AU AU58592/96A patent/AU701992B2/en not_active Ceased
- 1996-05-15 ES ES96920210T patent/ES2197239T3/es not_active Expired - Lifetime
1997
- 1997-11-14 MX MX9708777A patent/MX9708777A/es not_active IP Right Cessation
- 1997-11-17 NO NO19975269A patent/NO318237B1/no not_active IP Right Cessation
1999
- 1999-05-05 US US09/305,413 patent/US6153129A/en not_active Expired - Fee Related
2000
- 2000-06-06 US US09/587,821 patent/US6358443B1/en not_active Expired - Fee Related
2001
- 2001-12-06 US US10/006,991 patent/US6726860B2/en not_active Expired - Fee Related
2004
- 2004-02-23 US US10/784,474 patent/US7037450B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SK283128B6 (sk)	2003-02-04
US20020135085A1 (en)	2002-09-26
EP0827396B1 (en)	2003-04-09
NO975269D0 (no)	1997-11-17
AU701992B2 (en)	1999-02-11
RU2159148C2 (ru)	2000-11-20
HK1008937A1 (en)	1999-08-06
ES2197239T3 (es)	2004-01-01
US6153129A (en)	2000-11-28
CZ292969B6 (cs)	2004-01-14
HUP9802489A3 (en)	2000-06-28
MX9708777A (es)	1998-10-31
BR9608370A (pt)	1999-08-17
CA2221496A1 (en)	1996-11-21
KR100475476B1 (ko)	2006-03-27
DE69627320D1 (de)	2003-05-15
NO975269L (no)	1998-01-15
US6358443B1 (en)	2002-03-19
CN1184420A (zh)	1998-06-10
CZ358297A3 (cs)	1998-06-17
AU5859296A (en)	1996-11-29
ATE236618T1 (de)	2003-04-15
NZ308763A (en)	1998-11-25
KR19990014891A (ko)	1999-02-25
JPH11505250A (ja)	1999-05-18
HUP9802489A2 (hu)	1999-07-28
PL323382A1 (en)	1998-03-30
EP0827396A1 (en)	1998-03-11
CN1153567C (zh)	2004-06-16
CA2221496C (en)	2008-01-15
DK0827396T3 (da)	2003-08-04
JP4226649B2 (ja)	2009-02-18
PT827396E (pt)	2003-08-29
US20040253316A1 (en)	2004-12-16
US7037450B2 (en)	2006-05-02
WO1996036317A1 (en)	1996-11-21
HU224194B1 (hu)	2005-06-28
US6726860B2 (en)	2004-04-27
PL184484B1 (pl)	2002-11-29
US5922253A (en)	1999-07-13
SK153797A3 (en)	1998-09-09
DE69627320T2 (de)	2004-03-04

Legal Events

Date	Code	Title	Description
2010-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO318237B1 (no)	2005-02-21	Fremgangsmate i produksjonsskala for dannelse av mikropartikler
Bittner et al.	1999	Ultrasonic atomization for spray drying: a versatile technique for the preparation of protein loaded biodegradable microspheres
US6291013B1 (en)	2001-09-18	Emulsion-based processes for making microparticles
US20050220887A1 (en)	2005-10-06	Method for milling frozen microparticles
EP2377519B1 (en)	2016-03-23	Pharmaceutical Composition Comprising Octreotide Microparticles
CN109700780A (zh)	2019-05-03	一种高包封率的亲水性药物缓释微球及其制备方法
AU719944B2 (en)	2000-05-18	Production scale method of forming microparticles
WO2009039281A2 (en)	2009-03-26	Particle drying apparatus and methods for forming dry particles
Xie et al.	2019	Recent progress of supercritical carbon dioxide in producing natural nanomaterials
HK1008937B (en)	2005-04-01	Production scale method of forming microparticles
WO2006016981A2 (en)	2006-02-16	Production of porous materials by supercritical fluid processing
HK1161123B (en)	2016-10-07	Pharmaceutical composition comprising octreotide microparticles